CHECKMATE-227
Regimen
- Experimental
- nivolumab + ipilimumab
- Control
- platinum doublet (PD-L1≥1%) or nivo/chemo (PD-L1<1%)
Population
1L advanced NSCLC all PD-L1
Key finding
PD-L1≥1% mOS 17.1 vs 14.9 mo, HR 0.79 (0.67-0.94); dual-IO chemo-free option
Source: PMID 31562796
Timeline
- Enrollment start: 2015-08-05 📎
Guideline citations
- NCCN NSCLC Version 5.2026 (p.151)
- CSCO NSCLC 2025 ⚠️ OCR source